HOOKIPA Pharma
HOOK
HOOK was delisted on the 7th of August, 2025.
58 hedge funds and large institutions have $48M invested in HOOKIPA Pharma in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 26 reducing their positions, and 23 closing their positions.
36% more call options, than puts
Call options by funds: $195K | Put options by funds: $143K
2.45% less ownership
Funds ownership: 60.36% → 57.92% (-2.4%)
22% less funds holding
Funds holding: 74 → 58 (-16)
46% less capital inflows, than outflows
Capital inflows: $2.7M | Capital outflows: $5.03M
61% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 23
69% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.16M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$882K |
| 3 |
Renaissance Technologies
New York
|
+$157K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$130K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$91.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.37M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$831K |
| 3 |
State Street
Boston,
Massachusetts
|
-$421K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$274K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$212K |
HOOK Hedge Fund Activity: Q2 2022 in Review
58 of the 5,964 institutional investors tracked by Wall St. Rank reported a position in HOOKIPA Pharma (HOOK) for Q2 2022, worth a combined $48M — down 31% from $69.9M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of HOOK and 9 opened new positions — a net loss of 14 holders — while 26 trimmed existing stakes and 8 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.16M. The largest seller was BlackRock, cutting an estimated $1.37M.
- 58 institutional investors held HOOKIPA Pharma (HOOK) as of Q2 2022, down from 74 in Q1 2022.
- Funds reported $48M of HOOKIPA Pharma stock for Q2 2022, down 31% quarter-over-quarter.
- 9 funds opened new HOOKIPA Pharma positions in Q2 2022 and 23 closed out, a net change of -14 holders.
- The largest HOOKIPA Pharma buyer in Q2 2022 was Millennium Management, an estimated $1.16M added.
- The largest HOOKIPA Pharma seller in Q2 2022 was BlackRock, an estimated $1.37M sold.
Based on aggregated 13F filings for Q2 2022.